International Journal of Clinical Research

Objective To analyze the medical value of using dapagliflozin in the treatment of elderly chronic heart failure. Methods 80 elderly patients with chronic heart failure who received treatment from April 2023 to April 2024 were divided into a control group receiving routine anti heart failure treatment and an observation group receiving treatment with dapagliflozin. The cardiac indicators and activity endurance after treatment were compared. Results Before treatment, there was no statistically significant difference in the comparison of indicators (P>0.05). After treatment, the observation group had higher NT proBNP than the control group, higher left ventricular end diastolic diameter in LVED than the control group, and higher ejection fraction in LVEA than the control group. The observation group had a higher 6-minute walking distance than the control group, and the difference was statistically significant (P<0.05). Conclusion The use of dapagliflozin in the treatment of elderly chronic heart failure can improve myocardial metabolism, enhance cardiac function, and improve activity endurance.

Dapagliflozin; Elderly chronic heart failure; Heart function; Pharmacological effects; Renal reabsorption